Inotuzumab ozogamicin
Inotuzumab ozogamicin (pronounced as i noe tooz' ue mab oh zoe ga mye' sin) is a type of antibody-drug conjugate used in the treatment of certain types of cancer, specifically acute lymphoblastic leukemia (ALL).
Etymology
The name "Inotuzumab ozogamicin" is derived from its components: "Inotuzumab" is the monoclonal antibody that targets the CD22 antigen on the surface of B cells, and "ozogamicin" is the cytotoxic agent that is linked to the antibody.
Usage
Inotuzumab ozogamicin is used to treat adults with relapsed or refractory B-cell precursor ALL. It works by binding to the CD22 antigen on B cells, which allows the cytotoxic agent to enter the cell and cause cell death.
Side Effects
Common side effects of Inotuzumab ozogamicin include fatigue, fever, nausea, headache, abdominal pain, and thrombocytopenia. Severe side effects can include liver toxicity, infusion reactions, and hemorrhage.
Related Terms
- Monoclonal antibody
- Antibody-drug conjugate
- Acute lymphoblastic leukemia
- CD22 antigen
- Cytotoxic agent
- B cells
- Liver toxicity
- Infusion reactions
- Hemorrhage
External links
- Medical encyclopedia article on Inotuzumab ozogamicin
- Wikipedia's article - Inotuzumab ozogamicin
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski